Otsuka

Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies
Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies
BioSpace
Otsuka
Shape Therapeutics
gene therapy
AAV gene therapy
RNA editing
ocular diseases
Flag link:
Evaluating renal denervation rivals, FDA advisory panel backs ReCor, shuns Medtronic
Evaluating renal denervation rivals, FDA advisory panel backs ReCor, shuns Medtronic
Fierce Biotech
Medtech
FDA
renal denervation
Otsuka
Recor
Medtronic
hypertension
Flag link:
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
BioSpace
Sumitomo Pharma
Otsuka
clinical trials
ulotaront
schizophrenia
Flag link:
Hope springs for April inhibition
Hope springs for April inhibition
EP Vantage
Novartis
Chinook Therapeutics
April inhibition
M&A
Vera Therapeutics
Otsuka
RemeGen
Alpine Immune Sciences
Akso Biopharmaceutical
Aurinia Pharmaceuticals
Flag link:
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Yahoo/Benzinga
Otsuka
Lundbeck
FDA
Rexulti
Alzheimer's agitation
Flag link:
Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify
Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify
Fierce Pharma
Otsuka
Lundbeck
FDA
Abilify
Asimtufii
bipolar disorder
Flag link:
Sunovion, Otsuka randomize first patient for GAD Phase II/III study
Sunovion, Otsuka randomize first patient for GAD Phase II/III study
Clinical Trials Arena
Sunovion
Otsuka
clinicat trials
ulotaront
generalized anxiety disorder
Flag link:
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation
Fierce Pharma
Lundbeck
Otsuka
Rexulti
Alzheimer's disease
FDA
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion
Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion
Endpoints
Otsuka
Lundbeck
Alzheimer's disease
FDA
Rexulti
Alzheimer's disease agitation
Flag link:
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Flag link:
Alphabet's Verily to trial antidepressants
Alphabet's Verily to trial antidepressants
Beckers Hospital Review
Alphabet
Verily
Otsuka
antidepressants
centanafadine
clinical trials
Flag link:
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Flag link:
FDA greenlights Otsuka subsidiary's bile duct cancer drug
FDA greenlights Otsuka subsidiary's bile duct cancer drug
Endpoints
Otsuka
Taiho Oncology
Lytgobi
bile duct cancer
FDA
Flag link:
TCT 2022 – Otsuka’s renal denervation system shines
TCT 2022 – Otsuka’s renal denervation system shines
EP Vantage
Otsuka
Recor
devices
Medtech
TCT
renal denervation
Paradise
Flag link:
FDA accepts Otsuka, Lundbeck filing for long-acting schizophrenia drug, teeing up April decision date
FDA accepts Otsuka, Lundbeck filing for long-acting schizophrenia drug, teeing up April decision date
Fierce Pharma
Otsuka
Lundbeck
schizophrenia
FDA
bipolar disorder
Abilify Maintena
Flag link:
Akebia Regains Rights to Anemia Drug After Otsuka Partnership Dissolves
Akebia Regains Rights to Anemia Drug After Otsuka Partnership Dissolves
BioSpace
Otsuka
Akebia
vadadustat
anemia
Flag link:
Otsuka backs GrayMatters’ digital wearable tech for mental disorders
Otsuka backs GrayMatters’ digital wearable tech for mental disorders
Pharmaforum
Otsuka
GrayMatters Health
digital health
mental health
funding
Flag link:
Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs
Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs
Fierce Biotech
Sunovion
Otsuka
biobucks
neuropsychiatric
Flag link:
Otsuka 'Big Kidney' campaign targets HCPs in bid to shift diagnostic standards
Otsuka 'Big Kidney' campaign targets HCPs in bid to shift diagnostic standards
Fierce Pharma
kidney disease
Otsuka
physicians
autosomal dominant polycystic kidney disease
pharma marketing
Flag link:

Pages